Philipp E Hartrampf (Philipp Hartrampf)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 21

Top Topics

Benign Prostatic Hyperplasia

Radical Prostatectomy

Positron Emission Tomography

Top Venues

European journal of nuclear medicine and molecular imaging

Pharmaceuticals (Basel, Switzerland)

International journal of molecular sciences

This page only lists publications with an associated author ORCID identifier.

Publications

Sarah Schumann, Harry Scherthan, Philipp E Hartrampf, Lukas Göring, Andreas K Buck, Matthias Port, Michael Lassmann, Uta Eberlein
Modelling the In Vivo and Ex Vivo DNA Damage Response after Internal Irradiation of Blood from Patients with Thyroid Cancer. International journal of molecular sciences 25 (10) (2024)
Sarah Schumann, Harry Scherthan, Philipp E Hartrampf, Lukas Göring, Andreas K Buck, Matthias Port, Michael Lassmann, Uta Eberlein
Modelling the In Vivo and Ex Vivo DNA Damage Response after Internal Irradiation of Blood from Patients with Thyroid Cancer. International journal of molecular sciences 25 (10) (2024)
André Marquardt, Philipp E Hartrampf, Philip Kollmannsberger, Antonio Giovanni Solimando, Svenja Meierjohann, Hubert Kübler, Ralf Bargou, Bastian Schilling, Sebastian E Serfling, Andreas Buck, Rudolf A Werner, Constantin Lapa, Markus Krebs
Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors-A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures. Cancers 15 (2) (2023)
Philipp E Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, Hubert Kübler, Sebastian E Serfling, Wiebke Schlötelburg, Kerstin Michalski, Steven P Rowe, Martin G Pomper, Andreas K Buck, Uta Eberlein, Rudolf A Werner
SUV mean on baseline [ 18 F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [ 177 Lu]Lu-PSMA I&T. European journal of nuclear medicine and molecular imaging (2023)
Kerstin Michalski, Wiebke Schlötelburg, Philipp E Hartrampf, Aleksander Kosmala, Andreas K Buck, Stefanie Hahner, Andreas Schirbel
Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)
Kerstin Michalski, Wiebke Schlötelburg, Philipp E Hartrampf, Aleksander Kosmala, Andreas K Buck, Stefanie Hahner, Andreas Schirbel
Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)
Kerstin Michalski, Wiebke Schlötelburg, Philipp E Hartrampf, Aleksander Kosmala, Andreas K Buck, Stefanie Hahner, Andreas Schirbel
Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma. Pharmaceuticals (Basel, Switzerland) 17 (1) (2023)
André Marquardt, Philipp E Hartrampf, Philip Kollmannsberger, Antonio Giovanni Solimando, Svenja Meierjohann, Hubert Kübler, Ralf Bargou, Bastian Schilling, Sebastian E Serfling, Andreas Buck, Rudolf A Werner, Constantin Lapa, Markus Krebs
Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors-A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures. Cancers 15 (2) (2023)
André Marquardt, Philipp E Hartrampf, Philip Kollmannsberger, Antonio Giovanni Solimando, Svenja Meierjohann, Hubert Kübler, Ralf Bargou, Bastian Schilling, Sebastian E Serfling, Andreas Buck, Rudolf A Werner, Constantin Lapa, Markus Krebs
Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors-A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures. Cancers 15 (2) (2023)
Philipp E Hartrampf, Rudolf Werner, Andreas K Buck
[Theranostics for Well and Moderately Differentiated GEP-NEN]. Zentralblatt fur Chirurgie 147 (3) (2022)
Jörg Tamihardja, Leonie Zehner, Philipp E Hartrampf, Sinan Cirsi, Sonja Wegener, Andreas K Buck, Michael Flentje, Bülent Polat
Dose-Escalated Salvage Radiotherapy for Macroscopic Local Recurrence of Prostate Cancer in the Prostate-Specific Membrane Antigen Positron Emission Tomography Era. Cancers 14 (19) (2022)
Philipp E Hartrampf, Franz-Xaver Weinzierl, Sebastian E Serfling, Martin G Pomper, Steven P Rowe, Takahiro Higuchi, Anna Katharina Seitz, Hubert Kübler, Andreas K Buck, Rudolf A Werner
Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [ 177 Lu]Lu-PSMA I&T. Cancers 14 (3) (2022)
Stefanie Hahner, Philipp E Hartrampf, Patrick W Mihatsch, Marc Nauerz, Britta Heinze, Heribert Hänscheid, Carmina Teresa Fuß, Rudolf A Werner, Christina Pamporaki, Matthias Kroiss, Martin Fassnacht, Andreas K Buck, Andreas Schirbel
Targeting 11-Beta Hydroxylase With [131I]IMAZA: A Novel Approach for the Treatment of Advanced Adrenocortical Carcinoma. The Journal of clinical endocrinology and metabolism 107 (4) (2022)
Philipp E Hartrampf, Markus Krebs, Lea Peter, Marieke Heinrich, Julia Ruffing, Charis Kalogirou, Maximilian Weinke, Joachim Brumberg, Hubert Kübler, Andreas K Buck, Rudolf A Werner, Anna Katharina Seitz
Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach. Biology 11 (5) (2022)
Philipp E Hartrampf, Franz-Xaver Weinzierl, Anna Katharina Seitz, Hubert Kübler, Markus Essler, Andreas K Buck, Rudolf A Werner, Ralph A Bundschuh
Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy. The Prostate 82 (14) (2022)
Jörg Tamihardja, Leonie Zehner, Philipp E Hartrampf, Dominik Lisowski, Susanne Kneitz, Sinan Cirsi, Gary Razinskas, Michael Flentje, Bülent Polat
Salvage Nodal Radiotherapy as Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer Detected by Positron Emission Tomography Shows Favorable Outcome in Long-Term Follow-Up. Cancers 14 (15) (2022)
Patrick W Mihatsch, Matthias Beissert, Martin G Pomper, Thorsten A Bley, Anna K Seitz, Hubert Kübler, Andreas K Buck, Steven P Rowe, Sebastian E Serfling, Philipp E Hartrampf, Rudolf A Werner
Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT. Cancers 14 (2) (2022)
Philipp E Hartrampf, Constantin Lapa, Sebastian E Serfling, Andreas K Buck, Anna Katharina Seitz, Philipp T Meyer, Juri Ruf, Kerstin Michalski
Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [177Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome. Cancers 13 (17) (2021)
Alexander Weich, Rudolf A Werner, Andreas K Buck, Philipp E Hartrampf, Sebastian E Serfling, Michael Scheurlen, Hans-Jürgen Wester, Alexander Meining, Stefan Kircher, Takahiro Higuchi, Martin G Pomper, Steven P Rowe, Constantin Lapa, Malte Kircher
CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel, Switzerland) 11 (4) (2021)
Philipp E Hartrampf, Bernhard Petritsch, Andreas K Buck, Sebastian E Serfling
Pitfalls in PSMA-PET/CT: intensive bone marrow uptake in a case with polycythemia vera. European journal of nuclear medicine and molecular imaging 48 (5) (2020)
Kerstin Michalski, Juri Ruf, Christian Goetz, Anna Katharina Seitz, Andreas K Buck, Constantin Lapa, Philipp E Hartrampf
Prognostic implications of dual tracer PET/CT: PSMA ligand and [18F]FDG PET/CT in patients undergoing [177Lu]PSMA radioligand therapy. European journal of nuclear medicine and molecular imaging 48 (6) (2020)